Participants with known brain metastases
Participants with known metastases
Participants with known brain metastases should be excluded; screening for brain metastases with head imaging is not required
Participants with symptomatic brain metastases that require active treatment are excluded
Participants with known untreated brain or other central nervous system metastases are excluded
Participants with >  definitive lesions consistent with brain metastases
Participants with known untreated brain metastases should be excluded from this clinical trial; participants with a history of brain metastases that have been treated, are no longer taking corticosteroids, and have been stable on imaging for >=  weeks following the last date of treatment are permitted
Participants with known untreated brain metastases should be excluded from this clinical trial; participants with a history of brain metastases that have been treated, are no longer taking corticosteroids, and have been stable on imaging for >=  weeks following the last date of treatment are permitted
Participants with known untreated brain metastases should be excluded from this clinical trial; participants with a history of brain metastases that have been treated, are no longer taking corticosteroids, and have been stable on imaging for at least one month following the end of treatment are permitted.
Participants with known brain metastases should be excluded
Participants with active brain metastases
Participants with treated brain metastases are allowed; radiation must be completed at least  weeks prior to pembrolizumab dosing and participants must not require ongoing steroids; participants with untreated brain metastases that are all <  mm with no clinical symptoms or vasogenic edema may be allowed on study on a case-by-case basis on discussion with sponsor; these participants will require MRI monitoring every  weeks to ensure stability
Participants with known uncontrolled brain metastases will be excluded from this clinical
Participants with known brain metastases
PHASE II: Participants with known brain metastases should be excluded
Participants with known brain metastases
Participants with known brain metastases
Participants with known brain metastases
Participants with metastases
Participants with known brain metastases that are symptomatic and require corticosteroids are excluded
Participants with known brain metastases
Participants with known brain metastases, or any other metastases from cancer
Participants with known uncontrolled brain metastases
